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Abstract
Rationale: E-cigarettes vaporize propylene glycol/vegetable glycerin
(PG/VG), nicotine, and flavorings. However, the long-term health
effects of exposing lungs to vaped e-liquids are unknown.
Objectives: To determine the effects of chronic vaping on
pulmonary epithelia.
Methods:We performed research bronchoscopies on healthy
nonsmokers, cigarette smokers, and e-cigarette users (vapers) and
obtained bronchial brush biopsies and lavage samples from these
subjects for proteomic investigation. We further employed in vitro
and murine exposure models to support our human findings.
Measurements and Main Results: Visual inspection by
bronchoscopy revealed that vaper airways appeared friable and
erythematous. Epithelial cells from biopsy samples revealed
approximately 300 proteins that were differentially expressed in
smoker and vaper airways, with only 78 proteins being commonly
altered in both groups and 113 uniquely altered in vapers. For example,
CYP1B1 (cytochrome P450 family 1 subfamily B member 1),
MUC5AC (mucin 5 AC), and MUC4 levels were increased in vapers.
Aerosolized PG/VG alone significantly increased MUC5AC protein
in human airway epithelial cultures and in murine nasal epithelia
in vivo. We also found that e-liquids rapidly entered cells and
that PG/VG reduced membrane fluidity and impaired protein
diffusion.
Conclusions:We conclude that chronic vaping exerts marked
biological effects on the lung and that these effects may in part be
mediated by the PG/VG base. These changes are likely not harmless
and may have clinical implications for the development of chronic
lung disease. Further studies will be required to determine the full
extent of vaping on the lung.
Keywords: vaping; tobacco; mucin; chronic obstructive
pulmonary disease
E-cigarettes represent a relatively new
alternative to tobacco smoking that use a
propylene glycol/vegetable glycerin (PG/VG)
base to deliver nicotine and flavors
(collectively called an “e-liquid”) to the lung
via an electronic delivery device that
“vaporizes” the e-liquid into an aerosol (1).
People inhale tobacco smoke for the
psychotropic effects of nicotine (2). The
adverse health effects of chronically
inhaling combusted tobacco on the lung
have been well described and include
autophagy, DNA damage, goblet cell
metaplasia, increased inflammation, and
increased proteolysis in the lung. All of
these changes can lead to increased
incidences of chronic obstructive
pulmonary disease (COPD) and
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lung cancer, as well as significant
extrapulmonary effects including
cardiovascular disease (3–7). Whether or
not vaping is safe is highly controversial (8).
Proponents of vaping suggest that it is safer
than smoking and constitutes harm
reduction (9, 10). Opponents of vaping
have highlighted that vaped e-liquids
contain toxic chemicals including
formaldehyde and heavy metals, which
can cause respiratory disease (11–13).
The British government announced that
e-cigarettes are 95% safer than traditional
tobacco products and recommended that
people switch from tobacco to e-cigarettes
(14). In contrast, the U.S. Surgeon General’s
report (2016) stated “E-cigarette aerosol is
not harmless. It can contain harmful and
potentially harmful constituents including
nicotine,” suggesting that the U.S.
government is taking an alternative stance
(15). Moreover, this report noted a
concerning increase in vaping among
adolescents and never-before smokers in
young adults (15).
Several academic laboratories have
demonstrated that e-cigarette exposure
causes inflammation, oxidative stress,
and/or is toxic to multiple cell types
including pulmonary, endothelial, and stem
cells in vitro (16–18). Similarly, murine
e-cigarette exposures also caused
inflammation and oxidative stress (17, 18).
In contrast, emerging in vitro data from the
tobacco industry purport that vaping is
safer than conventional tobacco exposure
(19). However, the tobacco industry has
previously made erroneous claims of
modified risk, that is, that low-tar cigarettes
are safer (20). Thus, given the growing
popularity of vaping, it will be vital to
independently and agnostically determine
the potential for modified risk versus harm
of e-cigarettes. Martin and colleagues
performed a limited gene expression study
on nasal mucosa and found that 305 genes
were uniquely downregulated in vapers,
suggesting immunosuppression (21). In
an epidemiological study, McConnell
and colleagues found that “bronchitic
symptoms were associated with use of
e-cigarettes among adolescents” (22) and it
has been shown that vaper’s sputum has
proteomic alterations that are distinct from
tobacco exposure (23). However, to date,
in vivo data on the effects of e-cigarettes on
the lower airways are lacking. Because of
the paucity of information in this field, we
recruited healthy smokers, e-cigarette
users (vapers), and nonsmoking control
subjects and performed research
bronchoscopies to obtain brush biopsy and
lavage samples. In parallel, we also vaped
human bronchial epithelial cultures and
mice to test whether we could replicate our
in vivo observations.
Methods
Detailed methods are shown in the online
supplement.
Subject Recruitment and Bronchoscopy
We recruited healthy subjects as nonsmokers,
smokers, and vapers for our study.
Fiberoptic bronchoscopy was performed
according to American Thoracic Society
guidelines (24). Full details are provided in
the online supplement.
Merocyanine 540 Emission Scan
HEK293T cells were seeded into 96-well
plates (Corning) and human bronchial
epithelia were cultured on semipermeable
inserts in 24-well plates (Corning). Cells
were loaded with 100 mM merocyanine 540
(M540; Sigma-Aldrich) at 378C for 30
minutes, washed, and placed in Ringer’s
solution and emission spectra read
(excitation, 540 nm; emission, 550–700
nm), using an Infinite plate reader (Tecan).
Data were background subtracted, using




HEK293T cells were seeded on #1.5 glass
coverslips and transiently transfected with
constructs, using Lipofectamine 2000
(Thermo Fisher) as per the manufacturer’s
instructions. Cells were pretreated with
3% PG/VG or vehicle for 1 hour at 378C
before imaging. Fluorescence recovery after
photobleaching was performed 24–48
hours after transfection, using a Leica SP5
confocal microscope with a 633 1.30
numerical aperture glycerol immersion lens
as described (25).
Intracellular E-Liquid Imaging
HEK293T cells were seeded onto #1.5
glass coverslips for 24 hours, and primary
human bronchial epithelia were cultured
at the air–liquid interface for 4 weeks on
12-mm Transwell-clear membranes
(Corning). Cells were stained with 3 mM
calcein-AM (Thermo Fisher) for 30 minutes
at 378C and mounted in Attofluor imaging
chambers (Thermo Fisher). Images were
acquired before and after treatment with
150 ml of 3% (vol/vol) Pixie Dust (The
Vapor Girl) after exposure with the 405-nm
laser line and collected between 409 and
459 nm, using a Leica SP8 confocal
microscope with a 633 1.40 numerical
aperture glycerol immersion lens. The dose
of 3% e-liquid was selected as previously
it was shown that this causes moderate
toxicity (26).
Statistical Analysis
For statistical analysis, P< 0.05 was taken
as significant. Full statistical methods are
shown in the online supplement. In vivo
data are shown as mean6 SD and in vitro
data are shown as mean6 SE, where
n = the number of subjects, donors, or
replicates as applicable.
Results
Chronic Vaping Causes Erythematous
Airway Mucosa
We recruited healthy smokers, e-cigarette
vapers, and nonsmokers who met the
inclusion criteria. Spirometry was normal in
all groups, and no obvious underlying
abnormalities were detected (Table 1). To
confirm smoking/vaping patterns, each
subject completed a 2-week smoking
diary and we measured serum
cotinine/hydroxycotinine. Serum cotinine
and hydroxycotinine levels in smokers
(140.06 100.7 and 43.36 30.6,
respectively; n = 11) were similar to those
in vapers (97.26 72.2 and 26.16 21.7,
respectively; n = 10). Nonsmokers exhibited
no detectable level of either cotinine or
At a Glance Commentary
Scientific Knowledge on the
Subject: Limited information is
available on the effects of chronic
e-cigarette use on the lung.
What This Study Adds to the
Field: We show that chronic
e-cigarette use alters z200 proteins in
airway epithelia. Further confirmation
of these changes is provided by in vitro
and in vivo studies.
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hydroxycotinine (n = 13). Smokers
consumed 10.16 4.1 cigarettes per day and
9.56 6.2 pack-years (n = 9). E-cigarette use
was reported in both puff numbers and
milliliters of e-liquid consumed. Mean
e-cigarette consumption per day was
44.16 82.2 puffs or 11.46 17.0 ml/day.
Although the age of the smokers was
significantly higher (P = 0.019) than that of
nonsmokers and vapers, no significant
difference was observed in sex, race, or
body mass index (Table 1). Analysis of
BAL cytology showed no significant
difference (P. 0.05) in cell types among
subject cohorts (Table 1). Nonsmokers
tolerated the procedure well, with minimal
(if any) cough after intubation of the vocal
cords, and their airway mucosa were
healthy in appearance (uniformly pale
pink). In contrast, e-cigarette vapers
and healthy smokers generally coughed
throughout the procedure, and e-cigarette
vapers had more erythematous and irritable
airway mucosa than did nonsmokers (see
Figure E1 in the online supplement).
Vaping Alters Protein Expression in
Bronchial Epithelia
We used bronchoscopy to obtain brush
biopsies from the left and right main
bronchi or right bronchus intermedius.
Protein was extracted from the brushes
and stored at 2808C until all samples
could be concurrently analyzed by
liquid chromatography–tandem mass
spectrometry. For this analysis, samples
without visual blood contamination were
selected to avoid possible interference from
blood proteins, and hemoglobin levels were
used as covariate in the statistical model to
account for possible blood contamination.
The demographics and cytology pertaining
to the subjects selected for proteomic
analyses are shown in Table E1. After mass
spectrometry and normalization of label-
free quantification intensity data, three
samples were identified as outliers due to
higher nondetection rate in the hierarchical
clustering, principal component analysis, and
histogram of imputed data and were
removed. The final analysis of differential
protein expression included eight
nonsmokers, nine smokers, and nine vapers.
Changes in overall protein abundance
in smokers and vapers were different, as
evidenced by subject clustering versus
protein expression (Figure 1A). A volcano
plot also indicated the unique changes in
expression of smokers’ and vapers’ proteins
(Figure 1B). Our data revealed that 191
proteins were significantly (P, 0.05) up-
or downregulated in the vapers, compared
with 292 altered proteins in the smokers
(Figure 1C and Tables E3 and E4). Only
78 proteins were altered in both groups
(Figure 1C). Furthermore, vapers had 132
upregulated and 59 downregulated proteins
whereas smokers had 141 and 151
upregulated and downregulated proteins,
respectively (Figure 1C). The significantly
changed proteins common to smokers and
vapers are shown in Figure 2. Select protein
changes, along with a housekeeping protein
(GAPDH), were confirmed by Western blot,
and also shown as label-free quantification
(Figure E2). Of note, the secreted/gel-forming
mucin MUC5AC, and VAMP8 (vesicle-
associated membrane protein 8), a SNARE
(soluble N-ethylmaleimide-sensitive factor
attachment protein receptor) trafficking
protein that facilitates mucin secretion, were
upregulated in both groups (Figure 2, Figure
E2, and Tables E3 and E4). In contrast,
MUC4 was upregulated only in the vapers
(Table E3) whereas MUC5B was significantly
downregulated in the smokers (Table E4).
We then used pathway analysis to further
investigate these changes. Interestingly,
intracellular proteins from many organelles
were altered by both vaping and smoking,
with proteins from “membrane-bound
organelles” forming the largest group that were
altered (150 proteins). However, 14 pathways
that included proteins involved in organelle
membranes, early endosomes/trafficking,
macromolecular complexes, and mitochondria
were uniquely altered in vapers (Table E5).
PG/VG Exposure Alters Protein Levels
in Cultured Primary Human Airway
Epithelia and Murine Nasal Epithelia
In the proteomic study, the subjects were
allowed to vape their preferred e-liquid.
Given the heterogeneity in the more than
7,000 available flavors, we therefore
hypothesized that the observed changes
were due to either PG/VG and/or nicotine
rather than to the flavors. Thus, to better
understand what drove the protein changes
in vapers’ airways, we acutely exposed
primary human bronchial epithelial
cultures (HBECs) to aerosolized PG/VG
mixed at a 55/45 ratio, which is a common
ratio that is locally available. We exposed
HBECs to 36 puffs per day because 1) we
have previously shown that this dose affects
airway epithelia (26) and 2) this was close
to the median puffs per day in our vape
study group (i.e., 44 puffs). The aerosol was
diluted at various percentages of ambient
air, and cellular MUC5AC levels
were measured 24 hours later by
immunostaining. Our data indicated that a
30-minute exposure to PG/VG was
sufficient to drive a three- to fourfold
increase in MUC5AC levels (Figures 3 and
E3). Exposure to PG/VG containing nicotine
at 18 mg/ml (e.g., 111 mM nicotine) had
no further effect on MUC5AC expression,
indicating that these changes were driven
by PG/VG and not by nicotine (Figure 3).
We then subchronically (4 d) exposed
HBECs to PG/VG, which also increased
cellular MUC5AC levels (Figure E4). Because
CYP1B1 (cytochrome P450 family 1
Table 1. Demographic Details and Cytological Characteristics of BAL from Subjects
Categorized as Nonsmokers, Smokers, and Vapers
Nonsmokers Smokers Vapers




Age at bronchoscopy, yr 27.336 7.71 34.006 8.02 26.806 8.53
Height, cm 166.866 8.44 169.336 9.96 172.236 7.75
Weight, kg 79.046 22.38 81.376 19.84 85.946 15.16
Body mass index, kg/m2 28.136 6.54 28.416 6.65 29.106 5.35
FVC% 100.176 20.17 105.466 11.79 101.006 6.48
FEV1% 101.896 13.31 99.386 13.90 100.606 9.12
Polymorphonuclear cells, % 2.676 2.26 2.696 2.35 2.886 2.16
Macrophages, % 96.346 2.08 96.626 2.40 96.086 2.41
Eosinophils, % 0.436 0.84 0.516 0.59 0.406 0.49
Lymphocytes, % 0.126 0.31 0.006 0.00 0.006 0.00
Bronchial epithelial cells, % 0.436 0.63 0.186 0.31 0.646 0.73
Squamous epithelial cells, % 0.166 0.22 0.406 0.58 0.206 0.23
Data presented are mean6 SD, unless specified otherwise.
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subfamily B member 1) was upregulated in
vapers’ airways, we also tested whether this
protein was upregulated in vitro. Again, using
the acute vape protocol, we found that a
30-minute exposure significantly upregulated
CYP1B1 protein in HBECs (Figure E5).
Because PG/VG alone was sufficient to
increase intracellular MUC5AC levels in
HBECs, we then exposed wild-type mice
to aerosolized PG/VG. Mice are obligate
nose breathers and exhibit a high level of
filtration in the upper respiratory tract/nasal
passages (27). Accordingly, we then
measured intracellular MUC5AC levels in
murine nasal epithelia. We exposed mice to
PG/VG or air for 3 hours and harvested
nasal tissue samples 24 hours later. We
found that PG/VG increased MUC5AC
levels compared with air-exposed littermate
mice (Figures 4A and 4B). To validate the
antibody specificity, we ran samples from a
MUC5AC knockout mouse (Figure 4A).
As an additional validation, because the
Ca21-regulating protein STIM1 (stromal
interacting molecule 1) was specifically
upregulated in vapers, we also measured this
protein and found that it was also upregulated
by PG/VG exposure (Figures 4C and 4D). Of
note, Garcia-Arcos and colleagues showed that
prolonged exposure to vape causes airspace
enlargement with mucin, cytokine, and
protease expression in mouse lung (28).
PG/VG Affects Plasma Membrane
Fluidity and Impairs Protein Diffusion
Because our proteomic data indicated that
proteins involved in membrane biology
were most affected by vaping (Table E5), we
hypothesized that PG/VG could incorporate
into cellular membranes and alter protein
function. We have previously shown that
many e-liquids are autofluorescent in
the ultraviolet range (29) and that 3%
e-liquid addition typically causes moderate
toxicity (26). Using autofluorescence as an
indicator, we found that 3% Pixie Dust
e-liquid could rapidly enter HBECs
(Figure 5A). For HEK293T cells,
penetration was also observed to occur in a
dose-dependent fashion (Figure 5B and
Figure E6). Merocyanine 540 (M540) is a
fluorescent dye that incorporates into lipid
bilayers, including the plasma membrane,
and increases in fluorescence in direct
proportion to membrane fluidity (30). We
loaded M540 into HBECs to assess the
effects of PG/VG on membrane fluidity. To
calibrate the dye, we decreased membrane
fluidity by reducing the temperature with
ice-cold Ringer solution, which significantly
diminished M540 fluorescence (Figure 5C).
We then read M540 fluorescence in HBECs
loaded with M540, added PG/VG, and
reread fluorescence at 378C. Using this
approach, we found that PG/VG produced
a similar diminution of M540 fluorescence
as seen with reduced temperature
(Figure 5C). M540 fluorescence was also
sensitive to PG/VG in HEK293T cells in a
dose-dependent manner (Figure E7). Taken
together, these data suggested that PG/VG














































Figure 1. Vaping leads to unique changes in the airway proteome. (A) Heat map of differentially expressed proteins from bronchial brush biopsies from
the various groups. Vapers cluster together and are different from nonsmokers and smokers. (B) Log2 fold change in abundance versus significance for
all identified proteins for smokers (red dots) and vapers (black dots) relative to nonsmokers. The dashed line indicates a significance (P) value of 0.05.
(C) Venn diagram of increased (red) or decreased (blue) proteins in smokers and vapers relative to nonsmokers. NS = nonsmokers; S = smokers; V = vapers.
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further test the effects of PG/VG, we used
fluorescence recovery after photobleaching
to measure diffusion of the plasma
membrane proteins anoctamin 1 (Ano1)
and Orai1. In both cases, PG/VG exposure
decreased their diffusivity (Figures 5D and
5E), which is consistent with the decreased
membrane fluidity seen with M540.
Discussion
The lower airways are an important site
of pathology for many diseases including
asthma, chronic bronchitis, and cystic
fibrosis, suggesting that this region of the
respiratory tract is relevant to the study
of vaping. Researchers have previously
performed proteomic and genomic studies
on the airways of tobacco smokers (31, 32).
In common with these studies, we
detected changes in mucins, bacterial
permeability–increasing family members,
and epidermal growth factor receptor in
smokers’ airways, indicating that our
approach is valid (Table E4). Importantly,
our study is the first to look for proteomic
changes in the lower airways of vapers. We
deliberately chose younger subjects who
were all healthy, as indicated by normal
spirometry results, to avoid possible
confounders due to the development of
COPD or other pathology (Table 1).
However, whereas BAL cytology profiles
were similar across groups, bronchoscopy
revealed that vapers’ airways were more
erythematous and irritable to contact,
compared with those of nonsmokers
(Figure E1), suggesting that vaping is
not harmless.
We report here that approximately 300
and approximately 200 proteins were
significantly altered in smokers’ and vapers’
bronchial epithelia, respectively, with groups
of proteins associated with membranes
especially being altered in vapers (Figure 1
and Tables E3–E5). In Figure 2, we focused
on the commonly changed proteins, many of
which are known to be pathogenic. For
example, mucins are generated in goblet
cells, and their expression level increases
both with tobacco exposure and in COPD,
where they are associated with intraluminal
obstruction that serves as a nidus for airway
disease (33). We observed increased
intracellular MUC5AC and MUC4 in
vapers, which may be indicative of
airway remodeling and goblet cell
metaplasia/hyperplasia (Figure 2 and
Table E3). Furthermore, whereas
MUC5AC was upregulated in both vapers
and smokers, MUC4 was upregulated only
in vapers and MUC5B was downregulated
in smokers and unchanged in vapers.
Our in vitro and in vivo data suggested that
changes in MUC5AC levels were acutely
driven by PG/VG exposure (Figures 3 and
4). Given the established relevance of
mucins to airway disease including COPD,
the altered mucin expression profile may be
useful as a biomarker of exposure, and to
differentiate between vapers and smokers.
However, secreted MUC5AC levels are also
increased in vapers (23) and we hypothesize
that MUC5AC levels may also serve as a
biomarker of harm, because increased
mucin expression may be indicative of
impending airway obstruction (34, 35).
Given the ubiquity of PG/VG as the base
vehicle in most (if not all) e-liquids, we
propose that its presumed safety now
urgently needs to be reevaluated because it
may induce increased mucin production (14).
Although PG/VG does not fluoresce,
many e-liquids are autofluorescent (29).
Accordingly, we used autofluorescence to
probe e-liquid distribution in vitro. Our
data indicated that components of the Pixie
Dust e-liquid rapidly penetrated cells
(Figures 5A and 5B, E6, and E7). Propylene
glycol (PG) is a common chemical
used to produce polyester and as a
deicer/antifreeze, as well as being a base
constituent in e-liquids. Intravenous PG
can cause acute renal and CNS toxicity
(36), and PG inhalation causes renal and
liver toxicity (37). PG inhibits renal glucose
transport and corneal Na1/K1 ATPase
activity (38, 39). Vegetable glycerin
(glycerol; VG) forms the backbone of many
glycerophospholipids in eukaryotic cell
membranes (40) and can incorporate
directly into membranes to increase their
stiffness (41). Both PG and VG are















































































Log2 Fold Change 
–3.50 3.50–1.75 1.750.00
Figure 2. Proteins commonly altered in vapers and smokers. Heat map of protein expression (log2
fold change and P, 0.05) for proteins that are commonly altered in vapers and smokers. Data from
bronchial brushings of nonsmokers (n = 8), smokers (n = 9), and vapers (n = 9).
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AQP3, which is expressed in the lung (42,
43), suggesting that they may reach and
disrupt intracellular membranes (44).
Although it is possible that nicotine and/or
flavors exerted effects, we speculate that at
least some of the changes seen in the
airways are due to interactions between
PG/VG and the lipid bilayers that bound all
organelles. Importantly, protein mobility is
an important indicator of function. Thus,
an increase in membrane rigidity and
decrease in protein movement may impair
the functions of multiple proteins, and may
also impair endocytosis and exocytosis,
which are strongly dependent on the
production of membrane vesicles that form
from existing membranes (45).
In our in vitro studies, we used both
neat and vaped e-liquids. Our previous
studies did not find any difference between
neat and vaped e-liquids, suggesting that
such an approach is valid (26). However,
we cannot exclude the possibility that
some pyrolysis occurred during aerosol
generation that could affect some readouts.
Using our previous studies as a guide, we
used approximately 30-minute exposure
sessions to 36 puffs for our in vitro studies.
How much e-liquid is deposited in the
lungs after vaping is not known, and
further studies will be needed to validate or
refute our approaches. Interestingly, the
predicted deposition of e-cigarette aerosol
in the lungs is approximately 25%, suggesting
that our exposure regimen using the
VC 10 smoking robot (Vitrocell Systems)
is valid (46).
The liver is the primary site of
xenobiotic metabolism. However, the lung
also plays a role in this process, and we
found that several xenobiotic enzymes were
altered in vapers’ airways (Tables E6 and
E7), suggesting that the lung reacted to the
chemical burden of vaping by increasing
its ability for xenobiotic detoxification.
For example, CYP1B1 was upregulated,
suggesting increased phase I metabolism,
which may lead to the generation of more
covalent adducts. Similar upregulation was
also observed in vape-exposed HBECs
(Figure E5), indicating that this is a direct
consequence of vaping. Conversely, phase II
metabolism proteins (i.e., glutathione
S-transferases) were downregulated,
indicating that the ability to conjugate and
solubilize chemicals may be diminished
(Tables E6 and E7). Covalent adducts
damage DNA, leading to cancer-causing
mutations, and can also post-translationally




































































Figure 3. Acute PG/VG exposure increases intracellular MUC5AC levels in cultured human bronchial epithelia. (A) Typical hematoxylin and eosin and
Alcian blue–periodic acid–Schiff staining of fixed bronchial cultures after acute air versus 36.8% PG/VG/nicotine exposures. (B) Representative confocal
microscopy images of fixed cultures stained with Hoechst (nuclei; blue), MUC5AC (green), and cilia (a-tubulin; white). (C) Mean log2 fold changes in
MUC5AC fluorescence after exposure to various doses of PG/VG (shaded columns) or PG/VG1 nicotine (solid columns). *P, 0.05, different air exposure
(i.e., 0% PG/VG). Data shown as means6 SEM. AB/PAS = Alcian blue–periodic acid–Schiff; H&E = hematoxylin and eosin; MUC5AC=mucin 5AC;
PG/VG= propylene glycol/vegetable glycerin.
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vapers are less likely to be exposed to
tar-phase metabolites than smokers, CYP1B1
is also involved in the metabolism of steroids,
bioflavonoids, and xenobiotic oxidation,
and the chemical components of e-liquids
may also be substrates for P450 proteins
(50–52). However, the metabolism of
e-liquid constituents in the lung and
elsewhere and their propensity for
mutagenesis are poorly understood.
Furthermore, although we recruited vapers
with minimal current combustible tobacco
use, a large number of vapers still smoke
combustible tobacco products (53),
suggesting that the altered xenobiotic
metabolism will be especially relevant to
dual or mixed users.
We also observed that 113 proteins
were uniquely changed in vapers (Figure 1
and Tables E3 and E4), and further
studies will be needed to understand their
implications. However, STIM1, an
endoplasmic reticulum–resident Ca21-
regulating protein, was uniquely upregulated
in vapers (Table E3 and Figure E2), and
this change was reprised after PG/VG
exposure in mice (Figures 4C and 4D).
STIM1 is ubiquitously expressed and
plays a critical role in Ca21 homeostasis
(54). Cellular Ca21 controls multiple
aspects of cell function including
apoptosis, cell division, gene expression,
and protein secretion (54). Altered STIM1
levels may thus be indicative of altered
Ca21 metabolism, which could have wide-
ranging implications. We also observed
that Toll-like receptor 3 was uniquely
downregulated in vapers (Table E3). Toll-
like receptor 3 recognizes double-stranded
RNA and plays a role in defense against
viral infections (55), suggesting that innate
defense against viruses may be impaired
in vapers. These data are consistent
with epidemiological observations that
vapers are three times more likely to
have a respiratory infection than are
nonsmokers (22).
Our study has two possible limitations:
First, we acknowledge that our sample size is
relatively low, resulting in limited statistical
power. However, we confirmed important
proteomic “hits” by an additional technique
(i.e., Western blotting) and our data
provide impetus for conducting larger,
multicenter studies to examine the effects
of vaping on the lung. Second, the vapers
were mostly ex-smokers, and so changes
should be interpreted in the context of
this background. Importantly, we could
replicate the changes in CYP1B1, MUC5AC,
and STIM1 experimentally (Figures 3, 4,
E3, and E6), suggesting that at least some
of the proteomic changes were a direct
consequence of vaping. For future studies, it
would be best to recruit vapers who are
never-smokers, but although this is ideal,
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Figure 4. Acute PG/VG exposure increases upper airway MUC5AC and STIM1 expression in mice. (A) Left: Representative Western blot of MUC5AC
from the nasal epithelia of wild-type mice after 3 hours of acute exposure to PG/VG or air (control). Right: Western blot probing for MUC5AC in wild-type
and MUC5AC knockout mice as an antibody control. (B) Densitometric analysis of MUC5AC expression in PG/VG- and air-exposed mice (n = 6 per
group). (C) Representative Western blot of STIM1 with GAPDH as the loading control in nasal epithelia of mice after 3 hours of exposure to PG/VG or air.
(D) Densitometric analysis of STIM1 expression normalized to GAPDH in PG/VG-exposed mice compared with air (both n = 6). *P< 0.05 in PG/VG
compared with air. Data shown as means6 SD. The numbers on Western blots indicate protein from individual mice. KO = knockout; MUC5AC =mucin
5AC; PG/VG = propylene glycol/vegetable glycerin; STIM1 = stromal interaction protein 1; WT =wild type.
ORIGINAL ARTICLE


















































































































Figure 5. PG/VG affects membrane fluidity and protein diffusion. (A) Confocal micrographs (x–z plane) of human bronchial epithelial cultures (HBECs)
stained with calcein (green) and Pixie Dust e-liquid excited at 405 nm (red). Representative images of three independent experiments were taken before
and 10 minutes after addition of e-liquid. The dashed yellow lines indicate the apical surface of the culture. (B) Representative x–y-plane confocal
micrograph of HEK293T cells (gray differential interference contrast image) before and after 5 minutes of exposure to Pixie Dust e-liquid (purple). (C)
Emission scan of merocyanine 540 (M540) in HBECs. Black circles, vehicle at 378C; red squares, 3% PG/VG at 378C; blue triangles, vehicle at 48C.
All n = 9 cultures from three separate donors. (D and E) Fluorescence recovery after photobleaching of (D) Orai1-YFP and (E) Ano1-GFP in HEK293T
cells after vehicle or 3% PG/VG exposure. Cells transfected with Orai1-YFP or Ano1-GFP were exposed to PG/VG for 1 hour before FRAP was measured.
Data shown as means6 SEM. All n = 12–16 cultures per group from three or four independent experiments. *P< 0.05. Ano1 = anoctamin 1; FRAP =
fluorescence recovery after photobleaching; GFP = green fluorescent protein; Orai1 = calcium release-activated calcium modulator 1; PG/VG= propylene
glycol/vegetable glycerin; RG = Ringer’s glucose; YFP = yellow fluorescent protein.
ORIGINAL ARTICLE
74 American Journal of Respiratory and Critical Care Medicine Volume 198 Number 1 | July 1 2018
 
there are practical limitations from a
recruiting standpoint because many vapers
also have a significant history of tobacco
use. However, Beane and colleagues
demonstrated that smoking cessation
reverses approximately 80% of tested genes
altered by smoking (56). Of note, CYP1B1
and some aldo-keto reductases were rapidly
reversible after smoking cessation, suggesting
that the changes in detoxifying proteins
are due to vaping (56).
E-cigarettes have been recommended
by some physicians as a smoking alternative/
cessation device (57). Here, we demonstrate
that vaping exerts marked and extensive
biological effects on human airways,
suggesting 1) that inhalation of e-cigarette
vapor is not without consequences and is
by no means innocuous and 2) that they
should not be prescribed as a safe or
harmless tobacco alternative. Finally,
although the implications of our proteomic
data are not yet fully understood, they
have generated several testable hypotheses
to be further explored. Given the extent
of the changes observed with vaping, we
propose that vaping be carefully monitored
and not promoted as a “safe” smoking
alternative and that the implications of
these changes should be extensively
investigated. n
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